Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...
The pharmaceutical giant just extended the lifespan of one of its top drugs.
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next three days. The ex-dividend date is ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...
Hey, can Pfizer break out of its multi-year rut? Now, a lot depends on the presentation because I haven’t seen any needle ...
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results